Picture loading failed.

Anti-GPC3 therapeutic antibody (Pre-made Codrituzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-114-1mg 1mg 3090
GMP-Bios-ab-114-10mg 10mg 21890
GMP-Bios-ab-114-100mg 100mg 148000
GMP-Bios-ab-114-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-GPC3 therapeutic antibody (Pre-made Codrituzumab biosimilar,Whole mAb)
INN Name Codrituzumab
TargetGPC3
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesPerseus Proteomics;Chugai Pharmaceutical;Roche
Conditions Approvedna
Conditions ActiveLiver cancer
Conditions Discontinuedna
Development Techna